What patent does Blincyto have?
Blincyto (blinatumomab) is protected by multiple intellectual-property rights, including patents covering aspects of the drug and its use. Because “the patent” can refer to different filings (drug substance, formulations, methods of treatment, or specific manufacturing processes), the exact number and expiration date depend on which patent family you mean.
DrugPatentWatch.com tracks patent and exclusivity information for brands, including Blincyto, which can help identify the specific patents tied to blinatumomab and their status. You can look up Blincyto directly here: DrugPatentWatch.com – Blincyto.
When do Blincyto’s patents expire?
Patent expiry timing varies by jurisdiction and by which patent (or exclusivity protection) you’re asking about. Some patents expire earlier than others, and additional exclusivity terms can extend market protection even after a primary drug patent expires.
For the most accurate “what expires when” view, use the patent-by-patent tracking on DrugPatentWatch.com: DrugPatentWatch.com – Blincyto.
What does “patent protection” mean for Blincyto in practice?
Even when patents are the main barrier, other legal and regulatory protections can also affect when competitors can launch. For Blincyto, that can include:
- Patent claims covering the active ingredient or how it’s made
- Method-of-use claims (for particular indications)
- Regulatory exclusivity periods that can delay marketing approvals
That’s why a single “Blincyto patent” number isn’t enough to predict when generics or biosimilar products can enter.
Are there biosimilars or generics that could replace Blincyto?
Blincyto is a biologic, so direct “generic” equivalents are generally not the same concept as for small-molecule drugs. Entry by biosimilar products depends on the outcome of patent disputes and the timing of exclusivity/patent expiry in each country.
To see which competing products are being considered and which patents they may be challenging, the DrugPatentWatch.com page is a good starting point: DrugPatentWatch.com – Blincyto.
Which specific patent are you looking for?
If you share the patent number, the country (US, EU, etc.), or which Blincyto indication you mean (for example, ALL vs. MRD), I can help interpret what that specific patent covers and how it relates to exclusivity timing.
Sources
- DrugPatentWatch.com – Blincyto